{
    "clinical_study": {
        "@rank": "126189", 
        "arm_group": [
            {
                "arm_group_label": "Aeolus", 
                "arm_group_type": "Experimental", 
                "description": "Automated control of FiO2"
            }, 
            {
                "arm_group_label": "Manual", 
                "arm_group_type": "Active Comparator", 
                "description": "Manual control of FiO2"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall objective of this study is to demonstrate that the Aeolus device providing\n      automated control of fraction of inspired oxygen (FiO2) adjustments in spontaneously\n      breathing infants with fluctuating arterial blood oxygen saturation levels is safe and\n      efficacious in the routine clinical environment.  Specifically, it is hypothesizes that the\n      Aeolus will perform as well or better than standard practice for maintaining infants'\n      arterial blood oxygen saturation in a target range while minimizing the exposure to elevated\n      levels of oxygen in the inspired gas."
        }, 
        "brief_title": "Aeolus vs Manual Control for Optimizing Oxygenation in Infants", 
        "condition": "Oxygen Titration in Preterm Infants to Manage Lung Disease", 
        "condition_browse": {
            "mesh_term": "Lung Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Preterm infants being treated with high flow nasal cannula therapy\n\n          2. A need for supplemental oxygen as demonstrated by an required FiO2 > 0.25 at\n             enrollment\n\n          3. Requiring a flow rate of greater than 2 L/min such that the assumed inspired oxygen\n             fraction matched delivered oxygen fraction (definition of HFNC).\n\n        Exclusion Criteria:\n\n          1. Major congenital abnormalities\n\n          2. Hemodynamic instability, defined as being outside of a normotensive range based on\n             each infant's individual characteristics\n\n          3. Seizures\n\n          4. Ongoing sepsis\n\n          5. Meningitis\n\n          6. Clinician's concern regarding stability of the infant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074774", 
            "org_study_id": "RP-NIAE2014001Reg"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aeolus", 
                "description": "Automated FiO2 regulator that responds to pulse oximetry measures", 
                "intervention_name": "Aeolus", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Manual", 
                "description": "Standard practice of manually titrating FiO2 as needed.", 
                "intervention_name": "Manual control", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 26, 2014", 
        "number_of_arms": "2", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA) Devices Division"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent time in target range for oxygen saturation by pulse oximetry", 
            "safety_issue": "No", 
            "time_frame": "24 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074774"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Vapotherm, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vapotherm, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}